HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+9.13%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.44B
AUM Growth
+$2.44B
(-9.4%)
Cap. Flow
-$376M
Cap. Flow
% of AUM
-15.43%
Top 10 Holdings %
Top 10 Hldgs %
44.28%
Holding
112
New
29
Increased
17
Reduced
20
Closed
38
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$106M |
| 2 |
CVS Health
CVS
|
$106M |
| 3 |
Bristol-Myers Squibb
BMY
|
$98.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
$92.3M |
| 5 |
Natera
NTRA
|
$89.7M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$111M |
| 2 |
Incyte
INCY
|
$93M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$79.2M |
| 4 |
AbbVie
ABBV
|
$78.9M |
| 5 |
IQVIA
IQV
|
$77.6M |
Sector Composition
| 1 | Healthcare | 90.66% |
| 2 | Consumer Discretionary | 4.55% |
| 3 | Real Estate | 2.63% |
| 4 | Financials | 1.91% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$21B
| $123M | 4.91% |
764,330
+4,650
| +0.6% | +$748K |
|
2
Biogen
BIIB
$19.4B
| $117M | 4.7% |
339,300
+258,790
| +321% | +$89.6M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $116M | 4.62% |
1,235,048
-490,602
| -28% | -$45.9M |
|
4
Petco
WOOF
$1.12B
| $111M | 4.43% |
4,944,450
+1,856,450
| +60% | +$41.6M |
|
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $106M | 4.25% |
+190,380
| New | +$106M |
|
6
Humana
HUM
$36.5B
| $106M | 4.23% |
239,030
-12,360
| -5% | -$5.47M |
|
|
7
CVS Health
CVS
$92.8B
| $106M | 4.23% |
+1,267,330
| New | +$106M |
|
8
Danaher
DHR
$147B
| $103M | 4.13% |
384,920
-150,750
| -28% | -$40.5M |
|
|
9
Bristol-Myers Squibb
BMY
$96B
| $98.5M | 3.94% |
+1,474,370
| New | +$98.5M |
|
|
10
Thermo Fisher Scientific
TMO
$186B
| $92.3M | 3.69% |
+182,970
| New | +$92.3M |
|
|
11
Natera
NTRA
$23.1B
| $89.7M | 3.58% |
+789,658
| New | +$89.7M |
|
12
Encompass Health
EHC
$12.3B
| $82.3M | 3.29% |
1,055,316
+50,000
| +5% | +$3.9M |
|
13
Medtronic
MDT
$119B
| $74.6M | 2.98% |
600,720
-195,390
| -25% | -$24.3M |
|
14
Align Technology
ALGN
$10.3B
| $72.6M | 2.9% |
118,780
+47,320
| +66% | +$28.9M |
|
15
Stryker
SYK
$150B
| $71M | 2.84% |
+273,190
| New | +$71M |
|
|
NVRO
16
DELISTED
NEVRO CORP.
NVRO
| $62.4M | 2.49% |
+376,330
| New | +$62.4M |
|
17
Maravai LifeSciences
MRVI
$350M
| $52.4M | 2.09% |
1,255,597
-1,157,115
| -48% | -$48.3M |
|
18
Boston Scientific
BSX
$156B
| $51.8M | 2.07% |
1,210,570
+35,750
| +3% | +$1.53M |
|
19
BioCryst Pharmaceuticals
BCRX
$1.74B
| $51.4M | 2.05% |
3,248,100
-1,638,340
| -34% | -$25.9M |
|
20
Envista
NVST
$3.52B
| $50.4M | 2.01% |
1,165,860
-269,510
| -19% | -$11.6M |
|
21
Universal Health Services
UHS
$11.6B
| $47.7M | 1.91% |
+325,577
| New | +$47.7M |
|
22
Zoetis
ZTS
$69.3B
| $42.7M | 1.71% |
229,170
-192,690
| -46% | -$35.9M |
|
23
Veeva Systems
VEEV
$44B
| $42.3M | 1.69% |
136,080
+50,180
| +58% | +$15.6M |
|
24
Amgen
AMGN
$155B
| $38.6M | 1.54% |
+158,280
| New | +$38.6M |
|
25
Neurocrine Biosciences
NBIX
$13.8B
| $38M | 1.52% |
+389,980
| New | +$38M |
|